Malaysia Pharmaceuticals & Healthcare Q4 2018
The Malaysian pharmaceutical market will benefit from a higher expenditure on healthcare, with the governmentannouncing that it aims to increase its annual budget allocation to the healthcare sector as part of its ongoing effort to improve thehealth and well-being of the population. Furthermore, we expect the removal of the 6% goods and service tax (GST) will reduce theprice of medicines not previously included on the zero-rating list, providing a short-term boost to drug spending in Malaysia.Concerns over the high prices of pharmaceuticals will remain a key theme in Malaysia in the long-term. As such, the Malaysiangovernment will continue to intervene and establish pharmaceutical price controls to increase the population's access to affordablemedicines.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook